Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Brainstorm Cell Therapeutics Inc. (BCLI)

1.7   -0.06 (-3.41%) 11-25 13:00
Open: 1.7 Pre. Close: 1.76
High: 1.77 Low: 1.69
Volume: 64,595 Market Cap: 62(M)

Technical analysis

as of: 2022-11-28 8:46:33 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.12     One year: 4.27
Support: Support1: 1.09    Support2: 0.9
Resistance: Resistance1: 2.67    Resistance2: 3.66
Pivot: 2.05
Moving Average: MA(5): 1.68     MA(20): 2.41
MA(100): 3.23     MA(250): 3.2
MACD: MACD(12,26): -0.5     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 28.9     %D(3): 25.6
RSI: RSI(14): 32
52-week: High: 4.69  Low: 1.09
Average Vol(K): 3-Month: 271 (K)  10-Days: 350 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BCLI ] has closed above bottom band by 36.9%. Bollinger Bands are 140.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.77 - 1.78 1.78 - 1.79
Low: 1.66 - 1.67 1.67 - 1.69
Close: 1.68 - 1.7 1.7 - 1.72

Company Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Headline News

Wed, 23 Nov 2022
Do Traders Think Brainstorm Cell Therapeutics Inc (BCLI) Can Keep Climbing Wednesday? - InvestorsObserver

Tue, 22 Nov 2022
Healthcare Stocks Making Moves Tuesday: PALI, BCLI, ACHV, MBRX, QTNT, CFMS, CDIO, ATNM - InvestorsObserver

Thu, 17 Nov 2022
BCLI: Receives a Refusal to File Letter from the FDA for NurOwn® BLA… - Yahoo Finance

Mon, 14 Nov 2022
BrainStorm Cell Therapeutics GAAP EPS of -$0.53 (NASDAQ:BCLI) - Seeking Alpha

Mon, 14 Nov 2022
Brainstorm Cell Therapeutics Inc. (BCLI) Q3 2022 Earnings Call Transcript - Seeking Alpha

Sun, 13 Nov 2022
BrainStorm Cell Therapeutics Q3 2022 Earnings Preview (NASDAQ:BCLI) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 37 (M)
Shares Float 30 (M)
% Held by Insiders 22.5 (%)
% Held by Institutions 10.6 (%)
Shares Short 2,690 (K)
Shares Short P.Month 1,980 (K)

Stock Financials

EPS -0.64
EPS Est Next Qtl -0.32
EPS Est This Year -0.58
EPS Est Next Year -1.18
Book Value (p.s.) 0.03
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -68.4
Return on Equity (ttm) -193.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.71
Qtrly Earnings Growth 0
Operating Cash Flow -20 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -2.67
PEG Ratio 0
Price to Book value 42.5
Price to Sales 0
Price to Cash Flow -3.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.